troglitazone has been researched along with Adenocarcinoma, Alveolar in 1 studies
Troglitazone: A chroman and thiazolidinedione derivative that acts as a PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS (PPAR) agonist. It was formerly used in the treatment of TYPE 2 DIABETES MELLITUS, but has been withdrawn due to hepatotoxicity.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Andela, VB | 1 |
| Altuwaijri, S | 1 |
| Wood, J | 1 |
| Rosier, RN | 1 |
1 other study available for troglitazone and Adenocarcinoma, Alveolar
| Article | Year |
|---|---|
Inhibition of beta-oxidative respiration is a therapeutic window associated with the cancer chemo-preventive activity of PPARgamma agonists.
Topics: Adenocarcinoma, Bronchiolo-Alveolar; Adenosine Triphosphate; Animals; Antineoplastic Agents; Apoptos | 2005 |